CDK4/6 Abemaciclib GEP-NETS

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

CLINICALTRIALS.GOV IDENTIFIER: NCT03891784

DRUG/TREATMENT: abemaciclib

PHASE: 2

STATUS: Recruiting

SPONSOR: University of Washington

Collaborator: Eli Lilly and Company

Dr. Heloisa Soares Discusses CDK4/6 abemaciclib GEP-NETS

DESCRIPTION:

This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

For more information on eligibility criteria, trial locations, study details, etc.,  go to ClinicalTrials.gov to view this trial here.

CONTACT/Principal Investigator:

David B. Zhen, MD

Fred Hutch/University of Washington Cancer Consortium

EMAIL: dbzhen@uw.edu